Sinigrin

Sinigrin (Allyl-glucosinolate) is an orally active glucosinolate found in cruciferous plants. Sinigrin possesses multiple activities such as anti-cancer, antibacterial, antifungal, anti-inflammatory, antioxidant, and inhibition of fat synthesis. Sinigrin can be used in the research of tumors, inflammatory, and metabolic diseases^[1][2][3][4]. In Vitro: Sinigrin (1-100 μg/mL; 1-8 days) inhibits lipid accumulation, downregulates the expression of adipogenesis-related genes, suppresses the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-18), and induces cell cycle arrest in 3T3-L1 cells. The mechanism involves activation of the AMPK pathway and inhibition of the MAPK pathway^[1].
Sinigrin (5-30 μM; 24-48 h) induces cell cycle arrest in the S phase and promotes apoptosis, while triggering ROS-dependent oxidative stress damage by inhibiting PI3K/AKT/mTOR phosphorylation in MCF-7 cells^[2]. In Vivo: Sinigrin (15-30 mg/kg; oral administration; 12 days) exerts anti-inflammatory and ameliorative effects in DSS (HY-116282C)-induced ulcerative colitis mouse models^[3].